On October 25, 2024 Pantherna Therapeutics GmbH and TQ Therapeutics GmbH reported a research collaboration to advance both of their proprietary platform technologies to include LNPs into an ultra-short extracorporeal cell therapy process.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pantherna Therapeutics GmbH, an mRNA-lipid nanoparticle (LNP) platform company dedicated to the research and development of innovative mRNA-based therapeutics team up with TQ Therapeutics GmbH, an advanced CGT company developing an ultrashort extracorporeal point-of-care process. The joint goal is to investigate novel strategies for combining both platforms on enhanced therapeutic cell generation. The eHorts focus on exploiting the individual platform advantages regarding flexibility, safety and eHicacy to obtain fast and cost-eHective cellular therapies. Both companies believe that combining the point of care process with LNP technology will have a major impact in solving the current challenges in cell-and-gene therapy to make cell therapies scalable and broadly accessible for many patients.

"A collaboration of visionary teams is the cornerstone of innovation. In Pantherna Therapeutics, TQx has found a partner with whom we believe we can revolutionize cell therapies as they exist today. By uniting our technologies, we are creating a new platform for the production of CAR-T cells, making them accessible to everyone." – Dr. Christian Eckert (CEO – TQ Therapeutics)

"Pantherna is pleased to collaborate with TQ Therapeutics on their novel extracorporeal process for the generation of autologous CAR-T cell therapies. Our proprietary PTX-LNPs will serve as a non-viral delivery vehicle for this innovative approach. Together, we aim to significantly advance cell therapy and provide new treatment options for patients." – Dr. Ansgar Santel (CEO – Pantherna Therapeutics)

(Press release, Pantherna Therapeutics, OCT 25, 2024, View Source [SID1234662193])